Drugs for Lennox-Gastaut Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 21)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
2 |
|
Rufinamide |
Approved |
Phase 3 |
|
106308-44-5 |
129228 |
Synonyms:
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
60231/4
Banzel
CGP-33101
E2080
E-2080
|
Inovelon
RUF331
RUF-331
Rufinamida
RUFINAMIDE
XILEP
|
|
3 |
|
Clobazam |
Approved, Illicit |
Phase 3 |
|
22316-47-8 |
2789 |
Synonyms:
1-Phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine
1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine
7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
Chlorepin
CLOBAZAM
Clobazamum
Clorepin
Frisium
H-4723
HR-376
|
LM-2717
Mystan
NSC-336279
Onfi
PERIZAM
SYMPAZAN
TAPCLOB
Urbadan
URBANOL
Urbanyl
|
|
4 |
|
Topiramate |
Approved |
Phase 3 |
|
97240-79-4 |
5284627 |
Synonyms:
[(1R,2S,6S,9R)-4,4,11,11-TETRAMETHYL-3,5,7,10,12-PENTAOXATRICYCLO[7.3.0.0^{2,6}]DODECAN-6-YL]METHYL SULFAMATE
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamic acid
2,3-4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
|
Epitomax
epitomax|Eprontia® (liquid formulation)|MCN-4853|RWJ-17021|Topamax®
MCN-4853
QUDEXY XR
RWJ-17021
RWJ-17021-000
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Tipiramic acid
Topamax
Topamax sprinkle
TOPIRAMATE
topiramate tablet
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
TPM
Trokendi XR
USL255
USL-255
|
|
5 |
|
Sodium fluoride |
Approved |
Phase 3 |
|
7681-49-4 |
|
Synonyms:
Fluoride, sodium
Fluorides, sodium
Fluorinse
Fluoristat
Fluoristats
NaF
Ossin
|
Ossins
Procter and gamble brand OF sodium fluoride
Sodium fluoride
Sodium fluorides
Zymafluor
Zymafluors
|
|
6 |
|
Ethanol |
Approved |
Phase 3 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
7 |
|
Strawberry |
Approved |
Phase 3 |
|
|
|
8 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
9 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
10 |
|
Fenfluramine |
Approved, Illicit, Investigational, Withdrawn |
Phase 3 |
|
458-24-2 |
3337 |
Synonyms:
(+-)-Fenfluramine
(±)-fenfluramine
1-(m-Trifluoromethyl-phenyl)-2-ethylaminopropane
2-Ethylamino-1-(3-trifluoromethylphenyl)propane
3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
3-(Trifluoromethyl)-N-ethyl-a-methylphenethylamine
3-(Trifluoromethyl)-N-ethyl-α-methylphenethylamine
Adifax®|Fintepla®|Pondimin®|ZX008
DL-Fenfluramine
Ethyl-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-amine
Fenfluramina
Fenfluramine
Fenfluramine hydrochloride
Fenfluramine hydrochloride, (+-)-isomer
Fenfluramine hydrochloride, R isomer
|
Fenfluramine hydrochloride, R-isomer
Fenfluramine, (+-)-isomer
Fenfluramine, R isomer
Fenfluramine, R-isomer
Fenfluraminum
Hydrochloride, fenfluramine
Isomeride
N-Ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine
N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine
N-Ethyl-a-methyl-3-trifluoromethylphenethylamine
N-Ethyl-α-methyl-3-trifluoromethylphenethylamine
Ponderax
Pondimin
Robins brand OF fenfluramine hydrochloride
|
|
11 |
|
Ezogabine |
Approved, Investigational |
Phase 3 |
|
150812-12-7 |
121892 |
Synonyms:
AWD-21360
AWD-21360|D-23129|ezogabine|Potiga®|Trobalt®|WAY-143841
D-23129
Ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
Ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamic acid
Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate
Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilic acid
Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride
EZG
Ezogabine
GKE-841
GW582892X
|
GW-582892X
N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamate ethyl ester
N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamate ethyl ester
N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester
Potiga
Retigabina
Retigabine
RTG
TROBALT
WAY-143841
|
|
12 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
13 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
14 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
15 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
16 |
|
GABA Agonists |
|
Phase 3 |
|
|
|
17 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
18 |
|
Listerine |
|
Phase 3 |
|
|
|
19 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
20 |
|
Serotonin Uptake Inhibitors |
|
Phase 3 |
|
|
|
21 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 3 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
Interventional clinical trials:
(show all 50)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome, A Pilot Study |
Completed |
NCT02731300 |
Phase 4 |
|
2 |
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution |
Recruiting |
NCT05044819 |
Phase 4 |
Cannabidiol |
3 |
Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects |
Withdrawn |
NCT01370486 |
Phase 4 |
melatonin;placebo |
4 |
An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPIDIOLEX®; GWP42003-P) |
Withdrawn |
NCT04133480 |
Phase 4 |
GWP42003-P |
5 |
A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome |
Unknown status |
NCT04611438 |
Phase 3 |
Cannabidiol |
6 |
Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome |
Completed |
NCT00518713 |
Phase 3 |
Clobazam Low Dose;Clobazam Medium Dose;Clobazam High Dose;Placebo |
7 |
A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome. |
Completed |
NCT00236756 |
Phase 3 |
topiramate |
8 |
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome |
Completed |
NCT00004776 |
Phase 3 |
topiramate |
9 |
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients |
Completed |
NCT01146951 |
Phase 3 |
Rufinamide (E2080);Placebo |
10 |
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome |
Completed |
NCT01160770 |
Phase 3 |
Clobazam |
11 |
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. |
Completed |
NCT02224690 |
Phase 3 |
GWP42003-P 20 mg/kg/day Dose;Placebo |
12 |
A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome |
Completed |
NCT01405053 |
Phase 3 |
Rufinamide;Any other approved Antiepileptic Drug |
13 |
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. |
Completed |
NCT02224560 |
Phase 3 |
GWP42003-P;Placebo control |
14 |
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients |
Completed |
NCT01151540 |
Phase 3 |
Rufinamide |
15 |
An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes. |
Completed |
NCT02224573 |
Phase 3 |
GWP42003-P |
16 |
A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension |
Recruiting |
NCT05219617 |
Phase 3 |
Carisbamate |
17 |
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2) |
Recruiting |
NCT05163314 |
Phase 3 |
Soticlestat |
18 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS) |
Recruiting |
NCT04938427 |
Phase 3 |
Soticlestat;Placebo |
19 |
A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults With LGS |
Active, not recruiting |
NCT03355209 |
Phase 3 |
ZX008 0.2 or 0.8 mg/kg/day;Matching Placebo |
20 |
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome |
Active, not recruiting |
NCT03936777 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride) |
21 |
RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old) |
Terminated |
NCT01668654 |
Phase 3 |
retigabine/ezogabine |
22 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome |
Terminated |
NCT02834793 |
Phase 3 |
Placebo;Perampanel |
23 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome |
Withdrawn |
NCT02318537 |
Phase 3 |
Cannabidiol Oral Solution;Placebo Solution |
24 |
Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome |
Completed |
NCT00162981 |
Phase 2 |
Clobazam Low Dose;Clobazam High Dose |
25 |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies |
Completed |
NCT03650452 |
Phase 2 |
TAK-935;Placebo |
26 |
RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome |
Recruiting |
NCT05339126 |
Phase 2 |
|
27 |
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks |
Recruiting |
NCT05626634 |
Phase 2 |
LP352 |
28 |
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies |
Recruiting |
NCT05364021 |
Phase 1, Phase 2 |
LP352;Placebo |
29 |
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1) |
Active, not recruiting |
NCT03635073 |
Phase 2 |
Soticlestat |
30 |
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy |
Active, not recruiting |
NCT02655198 |
Phase 2 |
Fenfluramine |
31 |
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox-Gastaut Syndrome |
Not yet recruiting |
NCT05066217 |
Phase 2 |
Clemizole HCl;Placebo to match EPX-100 |
32 |
Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome |
Terminated |
NCT01494584 |
Phase 2 |
ezogabine/retigabine |
33 |
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children |
Terminated |
NCT02815540 |
Phase 1, Phase 2 |
Cannabidiol |
34 |
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome |
Completed |
NCT03467113 |
Phase 1 |
ZX008 0.2 to 0.8 mg/kg/day;Cannabidiol |
35 |
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome |
Recruiting |
NCT03731715 |
Phase 1 |
Carisbamate |
36 |
Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome |
Active, not recruiting |
NCT04062981 |
Phase 1 |
Carisbamate |
37 |
The Clinical Research on PINS Vagus Nerve Stimulator for Treatment of Lennox-Gastaut in Children |
Unknown status |
NCT02632149 |
Early Phase 1 |
|
38 |
European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS). |
Completed |
NCT01991041 |
|
|
39 |
An Open-label Observation Study of Topiramate Administration as Adjuvant Therapy for Focal Epilepsy, Lennox-Gastaut Syndrome Epileptic Seizures and Generalized Tonoclonic Seizures in Adults and Children Aged 2 Years and Older |
Completed |
NCT00297349 |
|
Topiramate |
40 |
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome |
Completed |
NCT02175173 |
|
Rufinamide |
41 |
Epilepsy Phenome/Genome Project: A Phenotype/Genotype Analysis of Epilepsy |
Completed |
NCT00552045 |
|
|
42 |
Efficacy of the Ketogenic Diet -- a Blinded Study |
Completed |
NCT00004729 |
|
|
43 |
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome |
Available |
NCT03778424 |
|
Rufinamide |
44 |
An Extended Access Program (EAP) for Perampanel |
Available |
NCT02307578 |
|
Perampanel |
45 |
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome - PCORI |
Not yet recruiting |
NCT05374824 |
|
|
46 |
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) |
Not yet recruiting |
NCT05485831 |
|
Epidiolex 100 mg/mL Oral Solution |
47 |
Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot |
Not yet recruiting |
NCT05437393 |
|
|
48 |
Long-term Cardiac Monitoring in Epilepsy: Comparative Group Study to Assess Risk of Interictal and Ictal Cardiac Dysfunction |
Suspended |
NCT03955432 |
|
|
49 |
Turmeric as Treatment in Epilepsy |
Withdrawn |
NCT03254680 |
|
|
50 |
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy |
Withdrawn |
NCT02910297 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
clobazam
Clonazepam
|
COLBAZAM
|
|